Mechanisms of autoimmune hepatitis

Pediatric Transplantation

Volumn 8, Issue 6, 2004, Pages 589-593

  Vergani, Diego ^a   Mieli Vergani, Giorgina ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Autoantibodies; Autoimmune hepatitis; Liver transplantation; Molecular mimicry

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIGEN; CD45 ANTIGEN; LIVER ANTIGEN; MICROSOME ANTIBODY; SMOOTH MUSCLE ANTIBODY; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CONFERENCE PAPER; DISEASE COURSE; GENETIC PREDISPOSITION; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOHISTOCHEMISTRY; LIVER TRANSPLANTATION; MOLECULAR MIMICRY; T LYMPHOCYTE ACTIVATION;

ANTIGEN-PRESENTING CELLS; AUTOANTIBODIES; CD4-POSITIVE T-LYMPHOCYTES; CYTOCHROME P-450 CYP2D6; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER TRANSPLANTATION; MOLECULAR MIMICRY; T-LYMPHOCYTES;

EID: 11144219748     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2004.00288.x     Document Type: Conference Paper

References (48)

1. SENALDI G, PORTMANN B, MOWAT AP, MIELI-VERGANI G, VERGANI D. Immunohistochemical features of the portal tract mononuclear cell infiltrate in chronic aggressive hepatitis. Arch Dis Child 1992: 67: 1447-1453.
2. NOURI-ARIA KT, DONALDSON PT, HEGARTY JE, EDDLESTON AL, WILLIAMS R. HLA A1-B8-DR3 and suppressor cell function in first-degree relatives of patients with autoimmune chronic active hepatitis. J Hepatol 1985: 1: 235-241.
3. NOURI-ARIA KT, LOBO-YEO A, VERGANI D, MIELI-VERGANI G, EDDLESTON AL, MOWAT AP. T suppressor cell function and number in children with liver disease. Clin Exp Immunol 1985: 61: 283-289.
4. DONALDSON PT, DOHERTY DG, HAYLLAR KM, MCFARLANE IG, JOHNSON PJ, WILLIAMS R. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991: 13: 701-706.
5. NOURI-ARIA KT, HEGARTY JE, ALEXANDER GJ, EDDLESTON AL, WILLIAMS R. Effect of corticosteroids on suppressor-cell activity in 'autoimmune' and viral chronic active hepatitis. N Engl J Med 1982: 307: 1301-1304.
6. VENTO S, HEGARTY JE, BOTTAZZO G, MACCHIA E, WILLIAMS R, EDDLESTON AL. Antigen specific suppressor cell function in autoimmune chronic active hepatitis. Lancet 1984: 1: 1200-1204.
7. LOBO-YEO A, SENALDI G, PORTMANN B, MOWAT AP, MIELI-VERGANI G, VERGANI D. Class I and class II major histocompatibility complex antigen expression on hepatocytes: a study in children with liver disease. Hepatology 1990: 12: 224-232.
8. CHEN M, SHIRAI M, LIU Z, ARICHI T, TAKAHASHI H, NISHIOKA M. Efficient class II major histocompatibility complex presentation of endogenously synthesized hepatitis C virus core protein by Epstein-Barr virus-transformed B-lymphoblastoid cell lines to CD4(+) T cells. J Virol 1998: 72: 8301-8308.
9. LOBO-YEO A, ALVIGGI L, MIELI-VERGANI G, PORTMANN B, MOWAT AP, VERGANI D. Preferential activation of helper/inducer T lymphocytes in autoimmune chronic active hepatitis. Clin Exp Immunol 1987: 67: 95-104.
10. CZAJA AJ, DONALDSON PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 2000: 174: 250-259.
11. UNDERHILL J, MA Y, BOGDANOS DP, CHEESEMAN P, MIELI-VERGANI G, VERGANI D. Different immunogenetic background in autoimmune hepatitis type 1, type and autoimmune sclerosing cholangitis. J Hepatol 2002: 36(Suppl. 1): 156A.
12. WEN L, PEAKMAN M, MOWAT AP, et al. gamma/delta+ T cell clones from liver biopsies of children with autoimmune chronic active hepatitis (aCAH) and primary sclerosing cholangitis (aPSC) are cytotoxic to human liver target cells. J Hepatol 1991: 13: S80.
13. TAKEDA K, HAYAKAWA Y, VAN KAER L, MATSUDA H, YAGITA H, OKUMURA K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci USA 2000: 97: 5498-5503.
14. JENSEN DM, MCFARLANE IG, PORTMANN BS, EDDLESTON AL, WILLIAMS R. Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. New Engl J Med 1978: 299: 1-7.
15. MCFARLANE BM, MCSORLEY CG, VERGANI D, MCFARLANE IG, WILLIAMS R. Serum autoantibodies reacting with the hepatic asialoglycoprotein receptor protein (hepatic lectin) in acute and chronic liver disorders. J Hepatol 1986: 3: 196-205.
16. MA Y, GAKEN J, MCFARLANE BM, et al. Alcohol dehydrogenase: a target of humoral autoimmune response in liver disease. Gastroenterology 1997: 112: 483-492.
17. VERGANI D, MIELI-VERGANI G, MONDELLI M, PORTMANN B, EDDLESTON AL. Immunoglobulin on the surface of isolated hepatocytes is associated with antibody-dependent cell-mediated cytotoxicity and liver damage. Liver 1987: 7: 307-315.
18. MIELI-VERGANI G, VERGANI D, JENKINS PJ, et al. Lymphocyte cytotoxicity to autologous hepatocytes in HBsAg-negative chronic active hepatitis. Clin Exp Immunol 1979: 38: 16-21.
19. WEN L, PEAKMAN M, LOBO-YEO A, et al. T-cell-directed hepatocyte damage in autoimmune chronic active hepatitis. Lancet 1990: 336: 1527-1530.
20. LOHR H, MANNS M, KYRIATSOULIS A, et al. Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin Exp Immunol 1991: 84: 297-302.
21. LOHR H, TREICHEL U, PORALLA T, MANNS M, MEYER ZUM BUSCHENFELDE KH. Liver-infiltrating T helper cells in autoimmune chronic active hepatitis stimulate the production of autoantibodies against the human asialoglycoprotein receptor in vitro. Clin Exp Immunol 1992: 88: 45-49.
22. HOMBERG JC, ABUAF N, BERNARD O, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of 'autoimmune' hepatitis. Hepatology 1987: 7: 1333-1339.
23. GUEGUEN M, MEUNIER-ROTIVAL M, BERNARD O, ALVAREZ F. Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily. J Exp Med 1988: 168: 801-806.
24. MURATORI L, PAROLA M, RIPALTI A, et al. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut 2000: 46: 553-561.
25. VERGANI D. LKM antibody: getting in some target practice. Gut 2000: 46: 449-450.
26. LERI O, PAPARO BARBARO S, SINOPOLI MT, MARCELLI V, DE ROSA FG, DE LUCA D. Type 2 autoimmune hepatitis and hepatitis C viraemia. Riv Eur Sci Med Farmacol 1996: 18: 3-6.
27. MURATORI L, LENZI M, CATALETA M, et al. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol 1994: 21: 199-203.
28. VERGANI D, MIELI-VERGANI G. Type II autoimmune hepatitis: the conundrum of cytochrome P450IID6 [editorial; comment]. Clin Exp Immunol 1993: 92: 367-368.
29. YAMAMOTO AM, CRESTEIL D, BONIFACE O, CLERC FF, ALVAREZ F. Identification and analysis of cytochrome P450IID6 antigenic sites recognized by anti-liver-kidney microsome type-1 antibodies (LKM1). Eur J Immunol 1993: 23: 1105-1111.
30. KERKAR N, CHOUDHURI K, MA Y, et al. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 2003: 170: 1481-1489.
31. BOGDANOS DP, CHOUDHURI K, VERGANI D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver 2001: 21: 225-232.
32. MANNS MP, GRIFFIN KJ, SULLIVAN KF, JOHNSON EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991: 88: 1370-1378.
33. BOGDANOS D, LENZI M, OKAMOTO M, et al. Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA b51. Int J Immunopathol Pharmacol 2004: 17: 83-92.
34. VERGANI D, WELLS L, LARCHER VF, et al. Genetically determined low C4: a predisposing factor to autoimmune chronic active hepatitis. Lancet 1985: 2: 294-298.
35. DOHERTY DG, UNDERHILL JA, DONALDSON PT, et al. Polymorphism in the human complement C4 genes and genetic susceptibility to autoimmune hepatitis. Autoimmunity 1994: 18: 243-249.
36. AICHELE P, BACHMANN MF, HENGARTNER H, ZINKERNAGEL RM. Immunopathology or organ-specific autoimmunity as a consequence of virus infection. Immunol Rev 1996: 152: 21-45.
37. KERKAR N, HADZIC N, DAVIES ET, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998: 351: 409-413.
38. ANDRIES S, CASAMAYOU L, SEMPOUX C, et al. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. Transplantation 2001: 72: 267-272.
39. HERNANDEZ HM, KOVARIK P, WHITINGTON PF, ALONSO EM. Autoimmune hepatitis as a late complication of liver transplantation. J Pediatr Gastroenterol Nutr 2001: 32: 131-136.
40. HENEGHAN MA, PORTMANN BC, NORRIS SM, et al. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults. Hepatology 2001: 34: 464-470.
41. SALCEDO M, VAQUERO J, BANARES R, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 2002: 35: 349-356.
42. GAO E, LO D, CHENEY R, KANAGAWA O, SPRENT J. Abnormal differentiation of thymocytes in mice treated with cyclosporin A. Nature 1988: 336: 176-179.
43. BUCY PB, YAN XU X, LI J, HUANG GQ. Cyclosporin A-induced autoimmune disease in mice. J Immunol 1993: 151: 1039-1050.
44. SAKAGUCHI S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000: 101: 455-458.
45. SAKAGUCHI S, SAKAGUCHI N. Role of genetic factors in organ-specific autoimmune diseases induced by manipulating the thymus or T cells, and not self-antigens. Rev Immunogenet 2000: 2: 147-153.
46. WU DY, GOLDSCHNEIDER I. Cyclosporin A-induced autologous graft-versus-host disease: a prototypical model of autoimmunity and active (dominant) tolerance coordinately induced by recent thymic emigrants. J Immunol 1999: 162: 6926-6933.
47. DAMOISEAUX JG, VAN BREDA VRIESMAN PJ. Cyclosporin A-induced autoimmunity: the result of defective de novo T-cell development. Folia Biol 1998: 44: 1-9.
48. AGUILERA I, WICHMANN I, SOUSA JM, et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation. Clin Exp Immunol 2001: 126: 535-539.